Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Vapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference


Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Vapotherm high velocity therapy® products, which are used to treat patients of all ages suffering from respiratory distress, today announced the company will be participating in a fireside chat at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

A recording of the presentation will be available beginning on Monday, November 22, 2021, at 10:00 a.m. Eastern Time. Interested parties may access the presentation in the Events section of Vapotherm's Investor website at: http://investors.vapotherm.com/.

About Vapotherm

Vapotherm, Inc. (NYSE: VAPO) is a publicly traded developer and manufacturer of advanced respiratory technology based in Exeter, New Hampshire, USA. The Company develops innovative, comfortable, non-invasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 3.2 million patients have been treated with the use of Vapotherm high velocity therapy® systems. For more information, visit www.vapotherm.com.

Vapotherm high velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool for relieving respiratory distress?including hypercapnia, hypoxemia, and dyspnea. It allows for the fast, safe treatment of undifferentiated respiratory distress with one tool. The Precision Flow system's mask-free interface delivers optimally conditioned breathing gases, making it comfortable for patients and reducing the risks and care complexities associated with mask therapies. While being treated, patients can talk, eat, drink and take oral medication.

Website Information

Vapotherm routinely posts important information for investors on the Investor Relations section of its website, http://investors.vapotherm.com/. Vapotherm intends to use this website as a means of disclosing material, non-public information and for complying with Vapotherm's disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of Vapotherm's website, in addition to following Vapotherm's press releases, Securities and Exchange Commission ("SEC") filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, Vapotherm's website is not incorporated by reference into, and is not a part of, this document.


These press releases may also interest you

at 08:05
Antibe Therapeutics Inc. ("Antibe" or the "Company") announced that the Company sought an extension of its previously announced stay of proceedings ("Stay") under the Companies' Creditors Arrangement Act (the "CCAA") at a hearing before the Ontario...

at 08:05
This partnership between Vertedge Health Analytics and InHome Connect utilizes data analytics to align patients in value-based care plans with palliative care services, aiming to improve patient care experiences, minimize unnecessary care...

at 08:03
Legacy Medical Consultants (LMC) announces its newest product portfolio addition with the recent Q code approval for Reeva FTtm, a terminally sterilized, full-thickness, dual-layered amnion/chorion allograft designed for covering and protection...

at 08:00
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on hemostatic medical device technologies, today announced it has entered into distribution agreements for its revolutionary hemostatic gel, VETIGEL®, to be sold directly to...

at 08:00
The Honourable Ya'ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health, will host an event at the University of Manitoba to highlight the federal budget's investments to boost funding for research in Canada. A media...

at 08:00
BODYHEALTH® has announced its latest scientific breakthrough in supplement formulas: The newly enhanced PerfectAmino (a proprietary Essential Amino Acid blend), the brand's flagship product, has added Nucleic Acid Building Blocks to their tablet...



News published on and distributed by: